Literature DB >> 23980020

The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.

E Saladino1, F Fleres, S Irato, C Famulari, A Macrì.   

Abstract

Nowadays the standard clinical management for advanced epithelial ovarian cancer is constituted by primary cytoreductive surgery associated to adjuvant systemic chemotherapy. Even if this first-line chemotherapy shows a high rate of complete responses, the disease recurrences occur especially in stage-III patients. Actually an option for this subset of patients is represented by secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy that represents a promising therapy, having shown positive results in terms of median overall survival, progression free survival and overall survival. However, a much more research is still required especially by prospective randomised trials to improve outcomes in recurrent ovarian cancer.

Entities:  

Mesh：

Year:  2013        PMID： 23980020     DOI： 10.1007/s13304-013-0229-9

Source DB:  PubMed          Journal:  Updates Surg        ISSN： 2038-131X


  54 in total

Review 1.  Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer.

Authors:  K Jaaback; N Johnson
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

2.  Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery.

Authors:  S Fujimoto; M Takahashi; T Mutou; K Kobayashi; T Toyosawa; E Isawa; M Sumida; H Ohkubo
Journal:  Cancer       Date:  1997-03-01       Impact factor: 6.860

3.  Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.

Authors:  Sebastián Rufián; Francisco C Muñoz-Casares; Javier Briceño; Carlos J Díaz; María J Rubio; Rosa Ortega; Rubén Ciria; Manuel Morillo; Enrique Aranda; Jordi Muntané; Carlos Pera
Journal:  J Surg Oncol       Date:  2006-09-15       Impact factor: 3.454

4.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.

Authors:  N Bakrin; E Cotte; F Golfier; F N Gilly; G Freyer; W Helm; O Glehen; J M Bereder
Journal:  Ann Surg Oncol       Date:  2012-07-24       Impact factor: 5.344

5.  Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.

Authors:  Dennis S Chi; Kristina McCaughty; John P Diaz; Jae Huh; Sarah Schwabenbauer; Amanda J Hummer; Ennapadam S Venkatraman; Carol Aghajanian; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

6.  Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.

Authors:  Jaeman Bae; Myong Cheol Lim; Jae-Ho Choi; Yong-Joong Song; Kyoung-Soo Lee; Sokbom Kang; Sang-Soo Seo; Sang-Yoon Park
Journal:  J Gynecol Oncol       Date:  2009-06-29       Impact factor: 4.401

7.  Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Michael J Sundborg; G Scott Rose; Peter G Rose; Stephen C Rubin; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-11-19       Impact factor: 44.544

8.  Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin.

Authors:  Eelco de Bree; John Romanos; John Michalakis; Kostantinos Relakis; Vasilis Georgoulias; John Melissas; Dimitris D Tsiftsis
Journal:  Anticancer Res       Date:  2003 May-Jun       Impact factor: 2.480

9.  Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.

Authors:  M Deraco; S Virzì; D R Iusco; F Puccio; A Macrì; C Famulari; M Solazzo; S Bonomi; A Grassi; D Baratti; S Kusamura
Journal:  BJOG       Date:  2012-06       Impact factor: 6.531

10.  Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study.

Authors:  M Deraco; C R Rossi; E Pennacchioli; S Guadagni; D C Somers; N Santoro; F Raspagliesi; S Kusamura; M Vaglini
Journal:  Tumori       Date:  2001 May-Jun
View more
  6 in total

Review 1.  Consequences of defensive medicine, second victims, and clinical-judicial syndrome on surgeons' medical practice and on health service.

Authors:  Italia Maria Pellino; Gianluca Pellino
Journal:  Updates Surg       Date:  2015-12-09

Review 2.  Prophylactic negative pressure wound therapy in colorectal surgery. Effects on surgical site events: current status and call to action.

Authors:  Gianluca Pellino; Guido Sciaudone; Francesco Selvaggi; Silvestro Canonico
Journal:  Updates Surg       Date:  2015-04-29

3.  Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib.

Authors:  Zehua Wang; Jianwen Gao; Yuko Ohno; Haiou Liu; Congjian Xu
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-06       Impact factor: 3.333

4.  Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study.

Authors:  Antonio Macrì; Fabio Accarpio; Vincenzo Arcoraci; Francesco Casella; Franco De Cian; Pierandrea De Iaco; Elena Orsenigo; Franco Roviello; Giovanni Scambia; Edoardo Saladino; Marica Galati
Journal:  Pleura Peritoneum       Date:  2020-12-04

Review 5.  Culture models to define key mediators of cancer matrix remodeling.

Authors:  Emily Suzanne Fuller; Viive Maarika Howell
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

6.  Wernicke encephalopathy as rare complication of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Antonio Macrì; Francesco Fleres; Antonio Ieni; Maurizio Rossitto; Tommaso Mandolfino; Salvatore Micalizzi; Francesco Iaropoli; Carmelo Mazzeo; Massimo Trovato; Eugenio Cucinotta; Edoardo Saladino
Journal:  Int J Surg Case Rep       Date:  2015-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.